Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | AQP4 | P55087 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2664559 | 0.89 | RAB9A (0.46) | KDM4ERAB9AMAPTTSHRL3MBTL1 | |
| SCHEMBL2664620 | 0.87 | RAB9A (0.43) | KDM4ERAB9AMAPTTSHRL3MBTL1 | |
| SCHEMBL2664675 | 0.87 | GCK (0.44) | KDM4ERAB9AMAPTTSHRL3MBTL1 | |
| SCHEMBL2664560 | 0.86 | RAB9A (0.43) | KDM4ERAB9AMAPTTSHRL3MBTL1 | |
| SCHEMBL2664588 | 0.85 | KMT2A (0.50) | KDM4ERAB9AMAPTTSHRL3MBTL1 | |
| SCHEMBL2664735 | 0.83 | PPARG (0.39) | RAB9AMAPTNPC1HPGDCYP4F2 | |
| SCHEMBL2664666 | 0.83 | KDM4E (0.42) | KDM4ERAB9AMAPTTSHRL3MBTL1 | |
| SCHEMBL2664679 | 0.80 | LMNA (0.41) | KDM4ERAB9AMAPTTSHRL3MBTL1 | |
| SCHEMBL2649796 | 0.79 | GCK (0.54) | — | |
| SCHEMBL14505719 | 0.79 | GCK (0.45) | RAB9AMAPTNPSR1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| EP-1987831-A1 | COMPOUNDS EFFECTING GLUCOKINASE | AstraZeneca AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
| EP-1568367-B1 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2007-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207636-A1 | Compounds Effecting Glucokinase | GCKR, GCK, SLC5A2 | KDM4E 2280/4885RAB9A 3175/4885MAPT 4022/4885 |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | KDM4E 2280/4885RAB9A 3175/4885MAPT 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.